Skip to main content
Top
Published in: Endocrine 1/2017

Open Access 01-01-2017 | Original Article

CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease

Authors: Edyta Pawlak-Adamska, Irena Frydecka, Marek Bolanowski, Anna Tomkiewicz, Anna Jonkisz, Lidia Karabon, Anna Partyka, Oskar Nowak, Marek Szalinski, Jacek Daroszewski

Published in: Endocrine | Issue 1/2017

Login to get access

Abstract

Graves’ disease, an autoimmune disease with heterogeneous symptoms including Graves’ orbitopathy, has a combined genetic/environmental background, where variations within CD28/CTLA-4/ICOS genes are considered as disease markers.
Association of CD28c.17+3T>C(rs3116496), CTLA-4g.319C>T(rs5742909), CTLA-4c.49A>G(rs231775), CTLA-4g.*642AT(8_33), CT60(rs3087243), Jo31(rs11571302), ICOSc.1554+4GT(8_15) polymorphisms with susceptibility to Graves’ disease and clinical outcome was investigated. The study group comprised of 561 Polish Caucasians, including 172 unrelated Graves’ disease patients. CTLA-4c.49A>G, CTLA-4g.319C>T, and CT60 were genotyped by PCR–RFLP; Jo31 and CD28c.17+3C>T by minisequencing; CTLA-4g.*642AT(8_33) and ICOSc.1554+4GT(8_15)—PCR and fluorescence-based technique. CD28c.17+3T>C(rs3116496)T/CTLA-4g.319C>T(rs5742909)C/CTLA-4c.49A>G(rs231775)G/CTLA-4g.*642AT(8_33)(AT16–21)/CT60(rs3087243)G/Jo31(rs11571302)G/ICOSc.1554+4GT(8_15)(m) and TCA(AT<16)GT(m) haplotypes increased risk of Graves’ disease, especially in males, as well as overall Graves’ orbitopathy development with severe outcome. TCG(AT16–21)GG(l) haplotype increased risk of Graves’ disease and reduced the chance of successful medical treatment. Although this haplotype was mainly observed in patients without signs of Graves’ orbitopathy, if Graves’ orbitopathy developed it favored a Graves’ orbitopathy outcome. Haplotype TCA(AT>21)GT(m) increased Graves’ disease risk in women and, in all patients, was linked to Graves’ disease without Graves’ orbitopathy. TCG(AT<16)GG(m) haplotype was predominantly observed in patients without Graves’ orbitopathy, whereas TCA(AT16–21)GG(m) was absent in those patients. TCA(AT16–21)GG(m) occurred in patients with a mild Graves’ orbitopathy outcome. The marker CTLA-4g.*642AT(8_33) was the only independent Graves’ disease risk factor, whereas CT60 was an independent factor for disease progression. Sporadic Graves’ disease was related to presence of CTLA-4c.49A>G[A] and the rare CTLA-4g.319C>T[T] allele variant. Familial background of the disease was exclusively associated with CTLA-4g.*642AT(8_33)[AT>21]/[AT>21] genotype. CD28/CTLA-4/ICOS loci may confer inherited susceptibility to Graves’ disease or may be involved in susceptibility to Graves’ disease and play a pathogenetic role.
Appendix
Available only for authorised users
Literature
6.
go back to reference A. Bossowski, A. Stasiak-Barmuta, M. Urban, Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves’ disease. Horm. Res. 64, 189–197 (2005). doi:10.1159/000088875 PubMed A. Bossowski, A. Stasiak-Barmuta, M. Urban, Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves’ disease. Horm. Res. 64, 189–197 (2005). doi:10.​1159/​000088875 PubMed
7.
go back to reference N. Matsuoka, K. Eguchi, A. Kawakami, M. Tsuboi, H. Nakamura, H. Kimura, N. Ishikawa, K. Ito, S. Nagataki, Lack of B7–1/BB1 and B7–2/B70 expression on thyrocytes of patients with Graves’ disease. Delivery of costimulatory signals from bystander professional antigen-presenting cells. J. Clin. Endocrinol. Metab. 81, 4137–4143 (1996). doi:10.1210/jcem.81.11.8923872 PubMed N. Matsuoka, K. Eguchi, A. Kawakami, M. Tsuboi, H. Nakamura, H. Kimura, N. Ishikawa, K. Ito, S. Nagataki, Lack of B7–1/BB1 and B7–2/B70 expression on thyrocytes of patients with Graves’ disease. Delivery of costimulatory signals from bystander professional antigen-presenting cells. J. Clin. Endocrinol. Metab. 81, 4137–4143 (1996). doi:10.​1210/​jcem.​81.​11.​8923872 PubMed
8.
go back to reference T. Kouki, Y. Sawai, C.A. Gardine, M.E. Fisfalen, M.L. Alegre, L.J. DeGroot, CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves’ disease. J. Immunol. 165, 6606–6011 (2000). doi:10.4049/jimmunol.165.11.6606 CrossRefPubMed T. Kouki, Y. Sawai, C.A. Gardine, M.E. Fisfalen, M.L. Alegre, L.J. DeGroot, CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves’ disease. J. Immunol. 165, 6606–6011 (2000). doi:10.​4049/​jimmunol.​165.​11.​6606 CrossRefPubMed
9.
go back to reference Y. Ban, E.S. Concepcion, R.B. Villanueva, D.A. Greenberg, T.F. Davies, Y. Tomer, Analysis of immune regulatory genes in familial and sporadic Graves’ disease. J. Clin. Endocrinol. Metab. 89, 4562–4568 (2004). doi:10.1210/jc.2003-031693 CrossRefPubMed Y. Ban, E.S. Concepcion, R.B. Villanueva, D.A. Greenberg, T.F. Davies, Y. Tomer, Analysis of immune regulatory genes in familial and sporadic Graves’ disease. J. Clin. Endocrinol. Metab. 89, 4562–4568 (2004). doi:10.​1210/​jc.​2003-031693 CrossRefPubMed
10.
go back to reference M. Mäurer, S. Loserth, A. Kolb-Mäurer, A. Ponath, S. Wiese, N. Kruse, P. Rieckmann, A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 54, 1–8 (2002). doi:10.1007/s00251-002-0429-9 CrossRefPubMed M. Mäurer, S. Loserth, A. Kolb-Mäurer, A. Ponath, S. Wiese, N. Kruse, P. Rieckmann, A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics 54, 1–8 (2002). doi:10.​1007/​s00251-002-0429-9 CrossRefPubMed
11.
go back to reference S. Anjos, A. Nguyen, H. Ounissi-Benkalha, M.C. Tessier, C. Polychronakos, A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J. Biol. Chem. 277, 46478–46486 (2002). doi:10.1074/jbc.M206894200 CrossRefPubMed S. Anjos, A. Nguyen, H. Ounissi-Benkalha, M.C. Tessier, C. Polychronakos, A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J. Biol. Chem. 277, 46478–46486 (2002). doi:10.​1074/​jbc.​M206894200 CrossRefPubMed
12.
13.
go back to reference A. Pérez-García, R. de la Cámara, J. Román-Gómez, A. Jiménez-Velasco, M. Encuentra, J.B. Nieto, J. de la Rubia, A. Urbano-Ispizúa, S. Brunet, A. Iriondo, M. González, D. Serrano, I. Espigado, C. Solano, J.M. Ribera, J.M. Pujal, M. Hoyos, D. Gallardo, GVHD/immunotherapy committee of the Spanish group of hematopoietic stem cell transplantation. CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. Blood 110(1), 461–467 (2007). doi:10.1182/blood-2007-01-069781 CrossRefPubMed A. Pérez-García, R. de la Cámara, J. Román-Gómez, A. Jiménez-Velasco, M. Encuentra, J.B. Nieto, J. de la Rubia, A. Urbano-Ispizúa, S. Brunet, A. Iriondo, M. González, D. Serrano, I. Espigado, C. Solano, J.M. Ribera, J.M. Pujal, M. Hoyos, D. Gallardo, GVHD/immunotherapy committee of the Spanish group of hematopoietic stem cell transplantation. CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. Blood 110(1), 461–467 (2007). doi:10.​1182/​blood-2007-01-069781 CrossRefPubMed
14.
go back to reference A. Ligers, N. Teleshova, T. Masterman, W.X. Huang, J. Hillert, CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2, 145–152 (2001)CrossRefPubMed A. Ligers, N. Teleshova, T. Masterman, W.X. Huang, J. Hillert, CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2, 145–152 (2001)CrossRefPubMed
16.
go back to reference D.A. Chistiakov, K.V. Savost’anov, R.I. Turakulov, I.A. Efremov, L.M. Demurov, Genetic analysis and functional evaluation of the C/T(-319) and A/G(-1661) polymorphisms of the CTLA-4 gene in patients affected with Graves’ disease. Clin. Immunol. 118, 233–242 (2006). doi:10.1016/j.clim.2005.09.017 CrossRefPubMed D.A. Chistiakov, K.V. Savost’anov, R.I. Turakulov, I.A. Efremov, L.M. Demurov, Genetic analysis and functional evaluation of the C/T(-319) and A/G(-1661) polymorphisms of the CTLA-4 gene in patients affected with Graves’ disease. Clin. Immunol. 118, 233–242 (2006). doi:10.​1016/​j.​clim.​2005.​09.​017 CrossRefPubMed
17.
go back to reference S.M. Anjos, M.C. Tessier, C. Polychronakos, Association of the cytotoxic T lymphocyte-associated antigen 4 gene with type 1 diabetes: evidence for independent effects of two polymorphisms on the same haplotype block. J. Clin. Endocrinol. Metab. 89, 6257–6265 (2004). doi:10.1210/jc.2004-0881 CrossRefPubMed S.M. Anjos, M.C. Tessier, C. Polychronakos, Association of the cytotoxic T lymphocyte-associated antigen 4 gene with type 1 diabetes: evidence for independent effects of two polymorphisms on the same haplotype block. J. Clin. Endocrinol. Metab. 89, 6257–6265 (2004). doi:10.​1210/​jc.​2004-0881 CrossRefPubMed
18.
go back to reference H. Ueda, J.M.M. Howson, L. Esposito, J. Heward, H. Snook, G. Chamberlain, D.B. Rainbow, K.M.D. Hunter, A.N. Smith, G. Di Genova, M.H. Herr, I. Dahlman, F. Payne, D. Smyth, C. Lowe, R.C.J. Twells, S. Howlett, B. Healy, S. Nutland, H.E. Rance, V. Everett, L.J. Smink, A.C. Lam, H.J. Cordell, N.M. Walker, C. Bordin, J. Hulme, C. Motzo, F. Cucca, J.F. Hess, M.L. Metzker, J. Rogers, S. Gregory, A. Allahabadia, R. Nithiyananthan, E. Tuomilehto-Wolf, J. Tuomilehto, P. Bingley, K.M. Gillespie, D.E. Undlien, K.S. Rønningen, C. Guja, C. Ionescu-Tırgoviste, D.A. Savage, A.P. Maxwell, D.J. Carson, C.C. Patterson, J.A. Franklyn, D.G. Clayton, L.B. Peterson, L.S. Wicker, J.A. Todd, S.C.L. Gough, Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423(29), 506–511 (2003)CrossRefPubMed H. Ueda, J.M.M. Howson, L. Esposito, J. Heward, H. Snook, G. Chamberlain, D.B. Rainbow, K.M.D. Hunter, A.N. Smith, G. Di Genova, M.H. Herr, I. Dahlman, F. Payne, D. Smyth, C. Lowe, R.C.J. Twells, S. Howlett, B. Healy, S. Nutland, H.E. Rance, V. Everett, L.J. Smink, A.C. Lam, H.J. Cordell, N.M. Walker, C. Bordin, J. Hulme, C. Motzo, F. Cucca, J.F. Hess, M.L. Metzker, J. Rogers, S. Gregory, A. Allahabadia, R. Nithiyananthan, E. Tuomilehto-Wolf, J. Tuomilehto, P. Bingley, K.M. Gillespie, D.E. Undlien, K.S. Rønningen, C. Guja, C. Ionescu-Tırgoviste, D.A. Savage, A.P. Maxwell, D.J. Carson, C.C. Patterson, J.A. Franklyn, D.G. Clayton, L.B. Peterson, L.S. Wicker, J.A. Todd, S.C.L. Gough, Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423(29), 506–511 (2003)CrossRefPubMed
19.
go back to reference S.M. Anjos, W. Shao, L. Marchand, C. Polychronakos, Allelic effects on gene regulation at the autoimmunity-predisposing CTLA4 locus: a re-evaluation of the 3′ +6230G > A polymorphism. Genes Immun. 6, 305–311 (2005). doi:10.1038/sj.gene.6364211 CrossRefPubMed S.M. Anjos, W. Shao, L. Marchand, C. Polychronakos, Allelic effects on gene regulation at the autoimmunity-predisposing CTLA4 locus: a re-evaluation of the 3′ +6230G > A polymorphism. Genes Immun. 6, 305–311 (2005). doi:10.​1038/​sj.​gene.​6364211 CrossRefPubMed
20.
go back to reference S. Purohit, R. Podolsky, C. Collins, W. Zheng, D. Schatz, A. Muir, D. Hopkins, Y.H. Huang, J.X. She, Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. J. Autoimm. Dis. 2, 8 (2005). doi:10.1186/1740-2557-2-8 CrossRef S. Purohit, R. Podolsky, C. Collins, W. Zheng, D. Schatz, A. Muir, D. Hopkins, Y.H. Huang, J.X. She, Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. J. Autoimm. Dis. 2, 8 (2005). doi:10.​1186/​1740-2557-2-8 CrossRef
21.
22.
go back to reference X.B. Wang, M. Kakoulidou, R. Giscombe, Q. Qiu, D. Huang, R. Pirskanen, A.K. Lefvert, Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J. Neuroimmunol. 130, 224–232 (2002). doi:10.1016/S0165-5728(02)00228-X CrossRefPubMed X.B. Wang, M. Kakoulidou, R. Giscombe, Q. Qiu, D. Huang, R. Pirskanen, A.K. Lefvert, Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J. Neuroimmunol. 130, 224–232 (2002). doi:10.​1016/​S0165-5728(02)00228-X CrossRefPubMed
26.
go back to reference J. Daroszewski, E. Pawlak, L. Karabon, I. Frydecka, A. Jonkisz, M. Slowik, M. Bolanowski, Soluble CTLA-4 receptor an immunological marker of Graves’ disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. Eur. J. Endocrinol. 161, 787–793 (2009). doi:10.1530/EJE-09-0600 CrossRefPubMed J. Daroszewski, E. Pawlak, L. Karabon, I. Frydecka, A. Jonkisz, M. Slowik, M. Bolanowski, Soluble CTLA-4 receptor an immunological marker of Graves’ disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. Eur. J. Endocrinol. 161, 787–793 (2009). doi:10.​1530/​EJE-09-0600 CrossRefPubMed
27.
go back to reference E. Pawlak, I. Kochanowska, I. Frydecka, M. Bilińska, The soluble CTLA-4 receptor: a new marker in autoimmune diseases. Arch. Immunol. Ther. Ex. 53, 336–341 (2005) E. Pawlak, I. Kochanowska, I. Frydecka, M. Bilińska, The soluble CTLA-4 receptor: a new marker in autoimmune diseases. Arch. Immunol. Ther. Ex. 53, 336–341 (2005)
28.
go back to reference F.K. Kavvoura, T. Akamizu, T. Awata, Y. Ban, D.A. Chistiakov, I. Frydecka, A. Ghaderi, S.C. Gough, Y. Hiromatsu, R. Ploski, P.W. Wang, Y. Ban, T. Bednarczuk, E.I. Chistiakova, M. Chojm, J.M. Heward, H. Hiratani, S.H. Juo, L. Karabon, S. Katayama, S. Kurihara, R.T. Liu, I. Miyake, G.H. Omrani, E. Pawlak, M. Taniyama, T. Tozaki, J.P. Ioannidis, Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis. J. Clin. Endocrinol. Metab. 92, 3162–3170 (2007). doi:10.1210/jc.2007-0147 CrossRefPubMed F.K. Kavvoura, T. Akamizu, T. Awata, Y. Ban, D.A. Chistiakov, I. Frydecka, A. Ghaderi, S.C. Gough, Y. Hiromatsu, R. Ploski, P.W. Wang, Y. Ban, T. Bednarczuk, E.I. Chistiakova, M. Chojm, J.M. Heward, H. Hiratani, S.H. Juo, L. Karabon, S. Katayama, S. Kurihara, R.T. Liu, I. Miyake, G.H. Omrani, E. Pawlak, M. Taniyama, T. Tozaki, J.P. Ioannidis, Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis. J. Clin. Endocrinol. Metab. 92, 3162–3170 (2007). doi:10.​1210/​jc.​2007-0147 CrossRefPubMed
29.
go back to reference D. Pastuszak-Lewandoska, E. Sewerynek, D. Domańska, A. Gładyś, R. Skrzypczak, E. Brzeziańska, CTLA-4 gene polymorphisms and their influence on predisposition to autoimmune thyroid diseases (Graves’ disease and Hashimoto’s thyroiditis). Arch. Med. Sci. 8(3), 415–421 (2012). doi:10.5114/aoms.2012.28593 CrossRefPubMedPubMedCentral D. Pastuszak-Lewandoska, E. Sewerynek, D. Domańska, A. Gładyś, R. Skrzypczak, E. Brzeziańska, CTLA-4 gene polymorphisms and their influence on predisposition to autoimmune thyroid diseases (Graves’ disease and Hashimoto’s thyroiditis). Arch. Med. Sci. 8(3), 415–421 (2012). doi:10.​5114/​aoms.​2012.​28593 CrossRefPubMedPubMedCentral
30.
go back to reference B. Jurecka-Lubieniecka, R. Ploski, D. Kula, A. Krol, T. Bednarczuk, Z. Kolosza, A. Tukiendorf, S. Szpak-Ulczok, A. Stanjek-Cichoracka, J. Polanska, B. Jarzab, Association between age at diagnosis of Graves’ disease and variants in genes involved in immune response. PLoS ONE 8(3), e59349 (2013). doi:10.1371/journal.pone.0059349 CrossRefPubMedPubMedCentral B. Jurecka-Lubieniecka, R. Ploski, D. Kula, A. Krol, T. Bednarczuk, Z. Kolosza, A. Tukiendorf, S. Szpak-Ulczok, A. Stanjek-Cichoracka, J. Polanska, B. Jarzab, Association between age at diagnosis of Graves’ disease and variants in genes involved in immune response. PLoS ONE 8(3), e59349 (2013). doi:10.​1371/​journal.​pone.​0059349 CrossRefPubMedPubMedCentral
31.
go back to reference T. Bednarczuk, Y. Hiromatsu, T. Fukutani, K. Jazdzewski, P. Miskiewicz, M. Osikowska, J. Nauman, Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphims and non-genetic factors with Graves’ ophthalmopathy in European and Japanese population. Eur. J. Endocrinol. 148, 13–18 (2003). doi:10.1530/eje.0.1480013 CrossRefPubMed T. Bednarczuk, Y. Hiromatsu, T. Fukutani, K. Jazdzewski, P. Miskiewicz, M. Osikowska, J. Nauman, Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphims and non-genetic factors with Graves’ ophthalmopathy in European and Japanese population. Eur. J. Endocrinol. 148, 13–18 (2003). doi:10.​1530/​eje.​0.​1480013 CrossRefPubMed
32.
go back to reference M. Sahin, M.F. Erdogan, G. Erdogan, Cytotoxic T lymphocyte-associated molecule-4 polymorphisms in Turkish Graves’ disease patients and association with probability of remission after antithyroid therapy. Eur. J. Int. Med. 16, 352–355 (2005). doi:10.1016/j.ejim.2005.06.007 CrossRef M. Sahin, M.F. Erdogan, G. Erdogan, Cytotoxic T lymphocyte-associated molecule-4 polymorphisms in Turkish Graves’ disease patients and association with probability of remission after antithyroid therapy. Eur. J. Int. Med. 16, 352–355 (2005). doi:10.​1016/​j.​ejim.​2005.​06.​007 CrossRef
33.
go back to reference Y. Kinjo, N. Takasu, I. Komiya, T. Tomoyose, M. Takara, T. Kouki, Y. Shimajiri, K. Yabiku, H. Yoshimura, Remission of Graves’ hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene. J. Clin. Endocrinol. Metab. 87(6), 2593–2596 (2002). doi:10.1210/jcem.87.6.8612 PubMed Y. Kinjo, N. Takasu, I. Komiya, T. Tomoyose, M. Takara, T. Kouki, Y. Shimajiri, K. Yabiku, H. Yoshimura, Remission of Graves’ hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene. J. Clin. Endocrinol. Metab. 87(6), 2593–2596 (2002). doi:10.​1210/​jcem.​87.​6.​8612 PubMed
34.
go back to reference P.W. Wang, I.Y. Chen, S.H. Juo, E. Hsi, R.T. Liu, C.J. Hsieh, Genotype and phenotype predictors of relapse of Graves’ disease after antithyroid drug withdrawal. Eur. Thyroid. J. 1(4), 251–258 (2013). doi:10.1159/000342621 PubMed P.W. Wang, I.Y. Chen, S.H. Juo, E. Hsi, R.T. Liu, C.J. Hsieh, Genotype and phenotype predictors of relapse of Graves’ disease after antithyroid drug withdrawal. Eur. Thyroid. J. 1(4), 251–258 (2013). doi:10.​1159/​000342621 PubMed
35.
go back to reference K.W. Kim, Y.J. Park, T.Y. Kim, D.J. Park, K.S. Park, B.Y. Cho, Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves’ disease. Thyroid 17(12), 1229–1234 (2007). doi:10.1089/thy.2007.0011 CrossRefPubMed K.W. Kim, Y.J. Park, T.Y. Kim, D.J. Park, K.S. Park, B.Y. Cho, Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves’ disease. Thyroid 17(12), 1229–1234 (2007). doi:10.​1089/​thy.​2007.​0011 CrossRefPubMed
36.
go back to reference Y. Tomer, D.A. Greenberg, G. Barbesino, E. Concepcion, T.F. Davies, CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. J. Clin. Endocrinol. Metab. 86(4), 1687–1693 (2001). doi:10.1210/jcem.86.4.7372 PubMed Y. Tomer, D.A. Greenberg, G. Barbesino, E. Concepcion, T.F. Davies, CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. J. Clin. Endocrinol. Metab. 86(4), 1687–1693 (2001). doi:10.​1210/​jcem.​86.​4.​7372 PubMed
39.
go back to reference L. Bartalena, L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M. Mourits, P. Perros, K. Boboridis, A. Boschi, N. Currò, C. Daumerie, G.J. Kahaly, G.E. Krassas, C.M. Lane, J.H. Lazarus, M. Marinò, M. Nardi, C. Neoh, J. Orgiazzi, S. Pearce, A. Pinchera, S. Pitz, M. Salvi, P. Sivelli, M. Stahl, G. von Arx, W.M. Wiersinga, European group on Graves’ orbitopathy (EUGOGO). Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur. J. Endocrinol. 158(3), 273–285 (2008). doi:10.1530/EJE-07-0666 CrossRefPubMed L. Bartalena, L. Baldeschi, A. Dickinson, A. Eckstein, P. Kendall-Taylor, C. Marcocci, M. Mourits, P. Perros, K. Boboridis, A. Boschi, N. Currò, C. Daumerie, G.J. Kahaly, G.E. Krassas, C.M. Lane, J.H. Lazarus, M. Marinò, M. Nardi, C. Neoh, J. Orgiazzi, S. Pearce, A. Pinchera, S. Pitz, M. Salvi, P. Sivelli, M. Stahl, G. von Arx, W.M. Wiersinga, European group on Graves’ orbitopathy (EUGOGO). Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur. J. Endocrinol. 158(3), 273–285 (2008). doi:10.​1530/​EJE-07-0666 CrossRefPubMed
40.
go back to reference K. Suwalska, E. Pawlak, L. Karabon, A. Tomkiewicz, T. Dobosz, D. Urbaniak-Kujda, K. Kuliczkowski, D. Wolowiec, A. Jedynak, I. Frydecka, Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia (B-CLL) in the Polish population. Hum. Immunol. 69, 193–201 (2007). doi:10.1016/j.humimm.2008.01.014 CrossRef K. Suwalska, E. Pawlak, L. Karabon, A. Tomkiewicz, T. Dobosz, D. Urbaniak-Kujda, K. Kuliczkowski, D. Wolowiec, A. Jedynak, I. Frydecka, Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia (B-CLL) in the Polish population. Hum. Immunol. 69, 193–201 (2007). doi:10.​1016/​j.​humimm.​2008.​01.​014 CrossRef
Metadata
Title
CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
Authors
Edyta Pawlak-Adamska
Irena Frydecka
Marek Bolanowski
Anna Tomkiewicz
Anna Jonkisz
Lidia Karabon
Anna Partyka
Oskar Nowak
Marek Szalinski
Jacek Daroszewski
Publication date
01-01-2017
Publisher
Springer US
Published in
Endocrine / Issue 1/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1096-1

Other articles of this Issue 1/2017

Endocrine 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.